<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01890005</url>
  </required_header>
  <id_info>
    <org_study_id>MHST2013-05</org_study_id>
    <nct_id>NCT01890005</nct_id>
  </id_info>
  <brief_title>Low Dose Aspirin for the Prevention of Preeclampsia</brief_title>
  <official_title>Low Dose Aspirin Between 13 and 16 Weeks of Pregnancy for the Prevention of Preeclampsia. Double Blind, Randomized, Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Thomas Hospital, Panama</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saint Thomas Hospital, Panama</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preeclampsia is one of the three leading causes of maternal morbidity and mortality all over
      the world. The use of low dose aspirin has been mentioned in several studies with promising
      results. The investigators decided to evaluate the use of low dose aspirin, starting between
      13 and 16 weeks of pregnancy, based on clinical characteristics only to reduce the incidence
      of preeclampsia.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevention of preeclampsia</measure>
    <time_frame>6 months</time_frame>
    <description>The number of cases of preeclampsia that appear in both groups before 34 weeks of pregnancy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevention of preeclampsia at term</measure>
    <time_frame>6 months</time_frame>
    <description>The number of cases of preeclampsia that appear in both groups between 37 and 41 weeks of pregnancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stillbirth</measure>
    <time_frame>6 months</time_frame>
    <description>The number of cases of stillbirths that appear in both groups at any given time during pregnancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal deaths</measure>
    <time_frame>6 months</time_frame>
    <description>The number of cases of neonatal deaths that appear in both groups, regardless of the cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal intensive care unit admissions.</measure>
    <time_frame>28 days</time_frame>
    <description>The number of cases that require admittance to the Neonatal Intensive Care Unit in both groups in the first 28 days after birth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abruptio placenta</measure>
    <time_frame>6 months</time_frame>
    <description>The number of cases of abruptio placenta that appear in both groups at any given time during pregnancy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal Growth Restriction</measure>
    <time_frame>6 months</time_frame>
    <description>The number of cases of fetal growth restriction, defined as a fetal weight below the 10th percentile and an abnormal umbilical cord doppler that appear in both groups at any given time during pregnancy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">476</enrollment>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose aspirin (100 mg) starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (identical to low dose aspirin (100 mg)) starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Low dose aspirin (100 mg) starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.</description>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational age between 13 and 16 weeks of pregnancy

          -  High risk of preeclampsia, based in clinical risk factors as:

        Preeclampsia in a previous pregnancy Mother or sister that developed preeclampsia in a
        previous pregnancy Diabetes Mellitus (insulin dependant) Chronic Hypertension (with/without
        proteinuria) Body Mass Index &gt; 32 Multiple pregnancy Lupus or other autoimmune disorder
        Chronic Renal Disease.

        Exclusion Criteria:

          -  Blood coagulation disorders of any kind

          -  Peptic ulcers

          -  Allergy to aspirin

          -  Chronic use of anti-inflammatory drugs

          -  Fetus with mayor anomalies
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osvaldo Reyes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Thomas Maternity Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rodrigo Velardee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Thomas Maternity Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ameth Hawkins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Thomas Maternity Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Moreno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Thomas Maternity Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rodrigo Velarde, MD</last_name>
    <email>revelarde_14@yahoo.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Osvaldo Reyes, MD</last_name>
    <email>oreyespanama@yahoo.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Saint Thomas Maternity Hospital</name>
      <address>
        <city>Panama</city>
        <country>Panama</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rodrigo Velarde, MD</last_name>
      <email>revelarde_14@yahoo.es</email>
    </contact>
    <contact_backup>
      <last_name>Osvaldo Reyes, MD</last_name>
      <email>oreyespanama@yahoo.es</email>
    </contact_backup>
    <investigator>
      <last_name>Osvaldo Reyes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rodrigo Velarde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Panama</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2013</study_first_submitted>
  <study_first_submitted_qc>June 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2013</study_first_posted>
  <last_update_submitted>June 28, 2013</last_update_submitted>
  <last_update_submitted_qc>June 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Saint Thomas Hospital, Panama</investigator_affiliation>
    <investigator_full_name>Osvaldo A. Reyes T.</investigator_full_name>
    <investigator_title>Coordinator of Research</investigator_title>
  </responsible_party>
  <keyword>Preeclampsia</keyword>
  <keyword>Low dose aspirin</keyword>
  <keyword>Fetal growth restriction</keyword>
  <keyword>Neonatal death</keyword>
  <keyword>Stillbirth</keyword>
  <keyword>Abruptio placenta</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

